Lantheus drops as Truist downgrades after Q2 miss

Shares of Lantheus Holdings (NASDAQ:LNTH) fell ~4% on Tuesday after Truist downgraded the radiopharmaceutical company to Hold from Buy, citing concerns over its Q2 2025 financials, which missed Street forecasts last week.

Analyst Richard Newitter argued that LNTH stock could be range-bound for at least one to two quarters, as the company's Q2 print indicated its plans for double-digit revenue/EPS growth being pushed out to Q4 2026, which he said was “a bit beyond our horizon.”

While noting LNTH's post-earnings selloff, the analyst noted underappreciated value attributed to Lantheus’ (NASDAQ:LNTH) long-term pipeline and its double-digit revenue/EPS growth projected for Q4 2026 and beyond 2027.

However, Newitter argued that LNTH’s trading multiple will continue to be determined by how the company performs with its PET imaging agent, Pylarify, for which trends indicate a YoY and QoQ deceleration for at least another two quarters.

“As a result, we think it might not be until early to mid-2026 before investors start assigning potential credit for a 4Q26-2027 DD reacceleration story,” the analyst wrote, slashing his price target on LNTH to $63 from $111 per share.